Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | HTR1D | P28221 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | HTR7 | P34969 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quazinone SCHEMBL25297639 | 1.00 | PDE3B (0.62) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| Quazinone SCHEMBL2463520 | 0.76 | PDE3B (1.00) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| Quazinone SCHEMBL120976 | 0.76 | PDE3B (1.00) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| Quazinone SCHEMBL11279841 | 0.75 | PDE3B (0.97) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| SCHEMBL4578707 | 0.71 | PDE3B (0.62) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| SCHEMBL11821637 | 0.68 | PDE3B (0.62) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| SCHEMBL3963853 | 0.68 | ACE (0.46) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| SCHEMBL21257756 | 0.67 | MMP13 (0.51) | LMNACYP2D6MMP13ACECDK5 | |
| SCHEMBL11278398 | 0.67 | PDE3B (0.70) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11388525 | 0.66 | PDE3B (0.68) | PDE3BPDE3ALMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2023118113-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-06-29 | — | — | WO | claimed |
| EP-4201403-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | Som Innovation Biotech, S.L. (ES) | 2023-06-28 | — | — | EP | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| EP-2704560-B1 | ORGAN CARE SOLUTION FOR EX-VIVO MACHINE PERFUSION OF DONOR LUNGS | TRANSMEDICS INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-20190046528-A1 | METHOD OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH BY USING PHOSPHODIESTERASE 3 INHIBITOR | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2019-02-14 | — | — | US | claimed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | claimed |
| EP-0777482-B1 | COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES | HOECHST AG (DE) | 2001-11-14 | — | — | EP | claimed |
| US-6297243-B1 | TREATING OSTEOPENIA THAT ACCOMPANIES THE MENOPAUSE | NOVO NORDISK A/S (DK) | 2001-10-02 | — | — | US | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE3B 3/4885PDE3A 1/4885LMNA 3009/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885LMNA 16/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885LMNA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.